Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: GMPs, DXM, Pharmascience, Rock Creek

This article was originally published in The Tan Sheet

Executive Summary

Herbal firm crosses GMP, claims lines; Kentucky makes 8 to age-restrict DXM sales; Pharmascience expands with Quebec support; Rock Creek closes share offerings; and more news in brief.

You may also be interested in...



In Brief: Federal Microbeads Bill Advances; Avon Buyout Hoax? More

The Microbead-Free Waters Act of 2015 was approved via voice vote by the House Energy and Commerce Health Subcommittee May14; Avon says it has not received a buyout offer from PTG Capital Partners despite a May 13 SEC filing from the firm indicating as much. More news in brief.

Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation

Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.

Medtronic Issues Another Recall For The HeartWare VAD System

The latest recall for Medtronic's HeartWare Ventricular Assist Device (HVAD) System was triggered by reports of hardened driveline boot covers, which can make disconnecting the driveline from the controller difficult.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS107750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel